Don't get wound up: revised fluoroquinolone breakpoints for enterobacteriaceae and pseudomonas aeruginosa

32Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fluoroquinolones remain some of the more commonly prescribed antimicrobial agents in the United States, despite the wide array of reported side effects that are associated with their use. In 2019, the Clinical and Laboratory Standards Institute revised the fluoroquinolone antimicrobial susceptibility testing breakpoints for both Enterobacteriaceae and Pseudomonas aeruginosa. This breakpoint revision was deemed necessary on the basis of pharmacokinetic and pharmacodynamic analyses suggesting that the previous breakpoints were too high, in addition to the inability of the previous breakpoints to detect low-level resistance to this antibiotic class. In this minireview, we review the published data in support of this revision, as well as the potential challenges that these breakpoint revisions are likely to pose for clinical laboratories.

Cite

CITATION STYLE

APA

Van, T. T., Minejima, E., Chiu, C. A., & Butler-Wu, S. M. (2019). Don’t get wound up: revised fluoroquinolone breakpoints for enterobacteriaceae and pseudomonas aeruginosa. Journal of Clinical Microbiology, 57(7). https://doi.org/10.1128/JCM.02072-18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free